The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited distribution network for the drugs, according to documents obtained by 340B Report under a Freedom of Information Act (FOIA) request.
HRSA gave the company a choice in a March 29, 2017, letter. It said, “Celgene must ensure that the 340B ceiling price is available to covered entities that wish to purchase through” one of the specialty pharmacies in its network, or it “must accept into network any covered entity or covered entity’s contract pharmacy that is willing to abide by requirements that Celgene has established.”
The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited distribution network for the drugs, according to documents obtained by 340B Report under a Freedom of Information Act (FOIA) request.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
